<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710383</url>
  </required_header>
  <id_info>
    <org_study_id>BCF 06-2018</org_study_id>
    <nct_id>NCT02710383</nct_id>
  </id_info>
  <brief_title>Biomarker for Cystic Fibrosis</brief_title>
  <acronym>BioCyFi</acronym>
  <official_title>Biomarker for Cystic Fibrosis: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify biomarker/s for&#xD;
      Cystic fibrosis and to explore the clinical robustness, specificity, and long-term&#xD;
      variability of these biomarker/s&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CyFi) is a progressive hereditary disease with the prevalence of 1 in 2500.&#xD;
      CyFi is an autosomal recessive disease caused by pathogenic variant/s in the CFTR (Cystic&#xD;
      Fibrosis Transmembrane Conductance Regulator) gene encoding Cftr protein.&#xD;
&#xD;
      CyFi causes chronic respiratory damage. Pulmonary findings occur already in infancy, which&#xD;
      raises questions whether obstruction might be congenital. Thick, sticky mucus clogs the&#xD;
      airways, reduces muco-ciliary clearance and leads to problems with breathing and recurrent&#xD;
      bacterial (Pseudomonas aeruginosa) infections, which causes over time the formation of scar&#xD;
      tissue (fibrosis) and cysts in the lungs.There is no cure for CyFi; however, symptomatic&#xD;
      treatment can help relieve symptoms.&#xD;
&#xD;
      The aim of this study is to identify biomarkers for Cystic fibrosis disease and to explore&#xD;
      their clinical robustness, specificity, and long-term variability. An ideal biomarker plays&#xD;
      an essential role in the early diagnosis, prediction and therapeutic monitoring of a specific&#xD;
      disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Cystic fibrosis biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of Cystic fibrosis biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Nasal Congestion</condition>
  <condition>Lung Infection</condition>
  <condition>Breathlessness</condition>
  <condition>Clubbing Toes</condition>
  <condition>Meconium Ileus</condition>
  <condition>Failure to Thrive</condition>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Participants genetically diagnosed with Cystic fibrosis</arm_group_label>
    <description>Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (CentocardÂ®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants genetically diagnosed with Cystic fibrosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Informed consent is obtained from the participant or the parent/ legal guardian&#xD;
&#xD;
          -  The participant is aged between 2 months and 50 years&#xD;
&#xD;
          -  The diagnosis of Cystic fibrosis is genetically confirmed by CENTOGENE&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Informed consent is not obtained from the participant or from the parent/ legal&#xD;
             guardian&#xD;
&#xD;
          -  The participant is younger than 2 months or older than 50 years&#xD;
&#xD;
          -  The diagnosis of Cystic fibrosis is not genetically confirmed by CENTOGENE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Centogene GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>10001</zip>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Molecular and Medical Genetics, Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health</name>
      <address>
        <city>Lahore</city>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo 8</city>
        <zip>00800c</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Georgia</country>
    <country>India</country>
    <country>Pakistan</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Meconium Ileus</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

